2021年4月13日

切姆斯福德,馬薩諸塞州,美國切姆斯福德,質量。2012年1月3日,(全球通訊社)——布魯克斯自動化有限公司(納斯達克:brk),自動化的全球領先的提供商,真空,多個市場和儀表解決方案包括半導體製造業、生命科學、和清潔能源,今天宣布完成收購Celigo®細胞血細胞計數器產品線從Cyntellect Inc .)一家私人持有的生命科學公司總部設在聖地亞哥。引入市場在2010年初,Celigo已經成為最迅速采用細胞成像係統基於其獨特的高通量、易用性和可購性。安裝客戶基地Celigo包括許多頂尖的製藥、生物技術、全球和學術機構。作為交易的一部分,大多數Cyntellect以來員工支持Celigo《盜夢空間》被搬到布魯克斯附近設施業務,CA,提供無縫過渡的關鍵工程、製造和研發能力,以及基於領域的銷售和支持人員。總裁兼首席執行官史蒂夫•施瓦茨博士布魯克斯說:“Celigo細胞成像的產品線是一個令人印象深刻的除了我們的家庭獨立的儀器儀表產品使用我們的許多生命科學自動化樣品管理係統的客戶。它加入越來越多的高生產率自動化解決方案組合分析,處理和測試生物和複合樣品的前和後存儲在我們的自動化樣品管理係統”。Dr. Schwartz continued, "The Celigo cell cytometer enables microplate-based high-throughput, high-content, brightfield and fluorescence cellular imaging and analysis, with minimal sample manipulation." Saiid Zarrabian, President and CEO of Cyntellect, stated, "We are thrilled to have found a tremendous partner in Brooks to take Celigo to the next level. When combined with Brooks' world-class infrastructure, global commercial reach and worldwide customer support, Celigo will have the opportunity to penetrate markets that otherwise weren't accessible to Cyntellect. We are confident that Celigo's rapid early market penetration will be greatly accelerated by Brooks." The purchase price was disclosed as up to approximately $9.2 million with settlement of part of the purchase price deferred for a six month period. About Brooks Automation, Inc. Brooks is a leading worldwide provider of automation, vacuum and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies and global service capabilities provide customers speed to market, and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, we have been a leading partner to the global semiconductor manufacturing market and through product development initiatives and strategic business acquisitions; we have expanded our reach to meet the needs of customers in the life sciences industry, analytical & research markets and clean energy solutions. Brooks is headquartered in Chelmsford, MA, with direct operations in North America, Europe and Asia. For more information, please visit www.brooks.com . "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934 Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include statements regarding future adoption of new technologies and our ability to develop further our business. Factors that could cause results to differ from our expectations and other risks that we have identified are described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release. Mot-clé